IN2012DN03631A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03631A
IN2012DN03631A IN3631DEN2012A IN2012DN03631A IN 2012DN03631 A IN2012DN03631 A IN 2012DN03631A IN 3631DEN2012 A IN3631DEN2012 A IN 3631DEN2012A IN 2012DN03631 A IN2012DN03631 A IN 2012DN03631A
Authority
IN
India
Prior art keywords
canines
eye
carotenes
amounts
maladies
Prior art date
Application number
Inventor
Yuanlong Pan
Wei Wang
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of IN2012DN03631A publication Critical patent/IN2012DN03631A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in canines by administering to the canines an ophthalmic malady ameliorating amount of one or more carotenes. Generally, the carotenes are administered to the canines in amounts of from about 0.1 to about 5000 mg or in amounts of from about 0.1 to about 500 mg per day to ameliorate maladies such as impaired vision, cataracts, cloudy eye, retinal degeneration, eye injury caused by radiation, reducing or preventing a decline of social interaction, promoting overall health and wellness, improving the quality of life, and extending the prime for canines.
IN3631DEN2012 2009-10-30 2010-10-22 IN2012DN03631A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28017509P 2009-10-30 2009-10-30
PCT/US2010/002815 WO2011059474A1 (en) 2009-10-30 2010-10-22 Methods for maintaining eye health and ameliorating opthalmic maladies in canines

Publications (1)

Publication Number Publication Date
IN2012DN03631A true IN2012DN03631A (en) 2015-06-26

Family

ID=43991896

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3631DEN2012 IN2012DN03631A (en) 2009-10-30 2010-10-22

Country Status (12)

Country Link
US (1) US20120270954A1 (en)
EP (1) EP2493293B1 (en)
JP (1) JP6071554B2 (en)
CN (1) CN102686107A (en)
AU (1) AU2010318687B2 (en)
BR (1) BR112012010179A2 (en)
CA (1) CA2778229A1 (en)
ES (1) ES2566652T3 (en)
IN (1) IN2012DN03631A (en)
MX (1) MX2012004777A (en)
RU (1) RU2012122169A (en)
WO (1) WO2011059474A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6026719B2 (en) * 2010-08-31 2016-11-16 株式会社ダイセル Visual function preventive / improving agent
WO2013043366A1 (en) * 2011-09-20 2013-03-28 Nestec S.A. Methods and compositions for improving visual function and eye health

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2094060C1 (en) 1994-03-22 1997-10-27 Уфимский научно-исследовательский институт глазных болезней Eye ointment
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
US20020182736A1 (en) * 2001-04-02 2002-12-05 Trustees Of Tufts College Methods to measure lipid antioxidant activity
JP4615309B2 (en) 2002-05-17 2011-01-19 オセラ・ホールディング・インコーポレイテッド Improving the progression of cataracts and other eye diseases
EP2020243B1 (en) 2002-05-28 2018-08-15 AstraZeneca AB Topically applicable pharmaceutical preparation
CA2556223A1 (en) * 2004-03-10 2005-09-22 Trustees Of Tufts College Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
JP2008515778A (en) * 2004-08-18 2008-05-15 シリオン セラピューティクス， インコーポレイテッド Combination methods, compositions and therapies for treating ocular conditions with 13-cis-retinyl derivatives
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
JP2009538353A (en) * 2006-06-08 2009-11-05 ザ アイムス カンパニー Composition for promoting eye health
US8158667B2 (en) 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
EP2213303A4 (en) 2007-10-19 2011-12-28 R Tech Ueno Ltd Pharmaceutical composition for treatment of cataract
MX2010008720A (en) * 2008-02-06 2010-08-30 Procter & Gamble Compositions methods and kits for enhancing immune response to a respiratory condition.

Also Published As

Publication number Publication date
CN102686107A (en) 2012-09-19
EP2493293A4 (en) 2013-03-20
AU2010318687B2 (en) 2016-02-25
MX2012004777A (en) 2012-06-01
ES2566652T3 (en) 2016-04-14
WO2011059474A1 (en) 2011-05-19
EP2493293B1 (en) 2016-03-02
EP2493293A1 (en) 2012-09-05
JP6071554B2 (en) 2017-02-01
RU2012122169A (en) 2013-12-10
BR112012010179A2 (en) 2015-09-29
US20120270954A1 (en) 2012-10-25
JP2013509407A (en) 2013-03-14
AU2010318687A1 (en) 2012-05-24
CA2778229A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
MX2010003774A (en) Aqueous ophthalmic formulations.
MY151018A (en) Use of nutritional compositions for preventing disorders
WO2012158910A3 (en) Compositions and methods for treating retinal diseases
MY176679A (en) Use of nutritional compositions for preventing disorders
PH12018500401B1 (en) Antibodies specific for tgf-beta
ECSP099516A (en) SUPPLEMENTARY NUTRITIONAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES
NZ586003A (en) Antigen binding proteins that bind beta-amyloid peptide
MX2019004468A (en) Contact lens use in the treatment of an ophthalmologic condition.
WO2010105728A3 (en) Active retinal implant
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
MX354875B (en) Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders.
MX2007008848A (en) Methods and compositions for the treatment of ocular disorders.
PL2262476T3 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
WO2007136518A3 (en) Treatment of autoimmune disorders
CL2008003120A1 (en) Compounds derived from phenylalkyl-, phenylalkenyl-, phenylalkynyl amine, phenylthioalkylamine, phenylaminoalkylamine, phenylalkoxyamine and phenylalkylguanidine; pharmaceutical composition; and use of the compounds to treat an ophthalmological disorder or disease such as retinopathy, maculopathy, retinitis pigmentosa, uveitis, among others.
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
MY160052A (en) Alkoxy compounds for disease treatment
MX355606B (en) Methods for diagnosing and treating eye-length related disorders.
MX2007010752A (en) Ophthalmic uses of s1p receptor modulators.
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
IN2012DN03631A (en)
WO2012105854A3 (en) Compositions for administration to the eye
CN102776103A (en) Ginseng leaf wine
HK1077306A1 (en) Ocular gene therapy
EA201401133A1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISTURBANCES, CONNECTED WITH EXCESSIVE WEIGHT OR OBSERVATION (OPTIONS);